The Christie Charity
Ejaz A et.al Acquired haemophilia A diagnosed during pregnancy Obstetric medicine https://doi.org/10.1177/1753495X211049987
Sharpley et.al Is it time for a more holistic approach to the treatment of multiple myeloma Hemato , 2, 628–634. https://doi.org/10.3390/ hemato2040040
Sharpley F, et.al (2021) Autologous stem cell transplantation vs bortezomib based chemotherapy for the first‐line treatment of systemic light chain amyloidosis in the UK EJH https://doi.org/10.1111/ejh.13582
Sharpley F, et. al (2020) Myeloma Clinical Outcomes following the First Wave of COVID-19: Results from Thames Valley Cancer Alliance (UK) BJH DOI: 10.1111/bjh.17261
Sharpley FA & Lachmann HJ, Amyloidosis chapter in Kelley and Firestein Textbook of Rheumatology 11th edition
Djebbari F, et. al (2020) Myeloma care adaptations in the UK during SARS‐CoV‐2 pandemic: Challenges and measurable outcomes Eu. J. Haematol https://doi.org/10.1111/ejh.13479
Cohen O et.a.l (2020) The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis Eu. J. Haematol. DOI: 10.1111/ejh.13458
Milani P et. al (2020) Pomalidomide and dexamethasone grant rapid hematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid D.O.I 10.1080/13506129.2020.1767566.
Cohen OC, et. al (2020) The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis Blood Cancer Journal (2020) 10:60
Sharpley et. al (2020) Amyloidosis diagnosed in solid-organ transplant recipients, Transplantation 104(2):415-420
Cohen OC, et.al (2020) Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis Br.J. Haematol. 189(4):643-649. doi: 10.1111/bjh.16401.
Djebbari F, et. al (2020) Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients, PLoS ONE 15(2): e0229469
Sharpley FA, et.al (2019) Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis. Eu. J. Haematol. 104(3):230-235. doi: 10.1111/ejh.13366
Sharpley FA et.al (2019) Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma, Leukaemia & Lymphoma, DOI: 10.1080/10428194.2019.1683737
Manwani, R et.al. (2019) A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood doi.org/10.1182/blood.2019000834
Sharpley et.al (2019) Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era PLoS ONE 14(7): e0219857. https://doi.org/10.1371/journal.pone.0219857
Sharpley et. al. (2019) A twenty-four year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. Br J Haematol. 187 (5): 642-652
Sharpley et.al (2019) Cardiac Biomarkers Are Prognostic In Systemic Light Chain Amyloidosis With No Cardiac Involvement By Standard Criteria Haematologica 105(5):1405-1413
Manwani, R. et.al (2019) Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. B. J. Haematol. 187 (5): 638-641
Sharpley, F. A. et. al (2019). A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis. Blood Cancer J, 9(2)16.
Rowczenio D. et.al (2019) Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Hum Mutat. 40(1):90-96. doi: 10.1002/humu.23669.
Lane, T. et. Al (2019) Natural history, quality of life and outcome in cardiac transthyretin amyloidosis Circulation. 2019;140:16–26
Sharpley, F. A.et.al (2018). Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis. Br J Haematol. 183(4):557-563
Manwani, R. et.al. (2018) Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine Blood 16;132(7):761-764
Sharpley FA et al (2017) Inferior Clinical Outcomes with Fixed Duration Therapy for Transplant - Ineligible Myeloma Patients: UK Real World Data in Comparison with the FIRST Trial (MM-020) Blood 130:3404
Sharpley FA et.al (2017) Surveillance Functional Imaging Has Limited Role in Solitary Plasmacytomas: International Multi-Centre Study of Clinical Outcomes Am Soc Hematology 130 (Supplement 1): 5379
Maciocia N et. al (2017) Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. Br.J.Haematol. 176, 6: 908-917
King, A et.al. (2016) Multiple Myeloma in the very elderly patient challenges and solutions. Clinical Interventions in Aging (11): 423-425
Maciocia N et.al (2016) Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience Blood 128:3312
Maciocia, N. et.al (2015) Outcome of Pomalidomide Therapy in Relapsed/Refractory Myeloma: A UK Multicentre Experience. Clinical Lymphoma, Myeloma & Leukaemia 15 (3): 288-289
Sharpley, FA (2014) Missing the Beat: arrhythmia as a presenting feature of eosinophilic granulomatosis with polyangitis BMJ Case Rep 8;2014
Turner, J.D. et.al (2009) Wolbachia lipoprotein stimulates innate and adaptive immunity through TLR2/6 to induce disease manifestations of filariasis J. biol. Chem. 284(33): 22364–22378